PURPOSE: @entity283 ( @entity283 ) concerns are pivotal in choosing @entity263 therapy. However, concurrent @entity283 comparison between brachytherapy, external radiation, radical prostatectomy, and controls is hitherto lacking. @entity283 effects of hormonal adjuvants and of @entity5 control after therapy also lack prior characterization. @entity1 AND METHODS: A cross-sectional survey was administered to @entity1 who underwent brachytherapy, external-beam radiation, or radical prostatectomy during 4 years at an academic medical center and to age-matched controls. @entity283 among controls was compared with therapy groups. Comparison between therapy groups was performed using regression models to control covariates. @entity283 effects of @entity5 progression were evaluated. RESULTS: One thousand fourteen subjects participated. Compared with controls, each therapy group reported bothersome @entity250 ; radical prostatectomy was associated with adverse urinary @entity283 ; external-beam radiation was associated with adverse bowel @entity283 ; and brachytherapy was associated with adverse urinary, bowel, and sexual @entity283 (P < or =.0002 for each). Hormonal adjuvant symptoms were associated with significant impairment (P <.002). More than 1 year after therapy, several @entity283 outcomes were less favorable among subjects after brachytherapy than after external radiation or radical prostatectomy. Progression-free subjects reported better sexual and hormonal @entity283 than subjects with increasing @entity1486 (P <.0001). CONCLUSION: Long-term @entity283 after prostate brachytherapy showed no benefit relative to radical prostatectomy or external-beam radiation and may be less favorable in some domains. Hormonal adjuvants can be associated with significant impairment. Progression-free survival is associated with @entity283 benefits. These findings facilitate @entity1 counseling regarding @entity283 expectations and highlight the need for prospective studies sensitive to urinary irritative and hormonal concerns in addition to incontinence, @entity458 .

Comprehensive comparison of health-related quality of life after contemporary therapies for XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS'] @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer'] @entity283 :: ('OMIM:603663', 'Disease') :: ['Health-related quality-of-life', 'HRQOL'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity458 :: ('MESH:D020018', 'Disease') :: ['sexual, and bowel HRQOL domains'] @entity1486 :: ('354', 'Gene') :: ['prostate-specific antigen'] @entity250 :: ('MESH:D012735', 'Disease') :: ['sexual dysfunction']
@entity263 :: (MESH:D011471,Disease) :: ['localized prostate cancer']
